Skip to main content
. Author manuscript; available in PMC: 2023 Feb 1.
Published in final edited form as: Oncogene. 2022 Jul 20;41(34):4104–4114. doi: 10.1038/s41388-022-02416-5

Fig. 2. Orthogonal binding of anti-ROR1 Fab switches to effector cells and target cells.

Fig. 2.

(A) Lentiviral CAR transduction on MACS-purified human primary T cells was determined by flow cytometry using cetuximab (5 μg/mL) conjugated to Alexa Fluor 647; (B) The expression level of ROR1 on different target cells was compared by flow cytometry using R12 Fab-N (10 μg/mL) followed by R-Phycoerythrin-conjugated goat F(ab’)2 anti-human IgG, F(ab’)2 fragment pAbs (K562 and K562/ROR1) or Alexa Fluor 647-conjugated 52SR4 scFv-Fc (Raji, JeKo-1, and MDA-MB-231). (C) The binding of anti-ROR1 Fab switches (5 μg/mL) to sCAR-T cells and target cells was determined by flow cytometry using R-Phycoerythrin-conjugated goat F(ab’)2 anti-human IgG, F(ab’)2 fragment pAbs (y axis: normalized count; x axis: fluorescence).